Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17445611 | 1.00 | PRMT6 (0.53) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16473389 | 1.00 | PRMT6 (0.53) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12851609 | 0.92 | PRMT6 (0.48) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12851855 | 0.89 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12851647 | 0.89 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12386688 | 0.89 | PRMT6 (0.51) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16473357 | 0.89 | PRMT6 (0.44) | PRMT6P2RY12 | |
| SCHEMBL16998325 | 0.88 | PRMT6 (0.52) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL10072467 | 0.87 | PRMT6 (0.51) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16473413 | 0.87 | ADORA2A (0.47) | BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108800-A1 | METHOD FOR SYNTHESIZING NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108800-A1 | METHOD FOR SYNTHESIZING NUCLEIC ACID | RNGTT, NSUN2, NSUN3 | PRMT6 1105/4885PRKAB2 2128/4885PRKAG1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.